DOCSLIB.ORG

Rural Health Clinic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

N.C. DEPARTMENT OF HEALTH AND HUMAN SERVICES DIVISION OF HEALTH BENEFITS PHYSICIAN SERVICES FEE SCHEDULE PROVIDER SPECIALTY 075 TAXONOMY: 261QR1300X RURAL HEALTH CLINIC The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Policies on the DMA Web Site. Providers should always bill their usual and customary charges. Please use the monthly Medicaid Bulletin for additions, changes, and deletions to this fee schedule. Please Note: Colored coded text changes (If Any) - Additions (BLUE) , End-Dated (RED) . Updated 6/30/2021 CODE MOD DESCRIPTION FACILITY NON-FACILITY 0001A IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVE 40.00 40.00 0002A IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVE 40.00 40.00 0011A IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVE 40.00 40.00 0012A IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVE 40.00 40.00 0031A IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVE 40.00 40.00 01996 DAILY HOSPITAL MANAGEMENT OF CONTINUOUS SPINAL DRUG ADMINIST 42.14 42.14 0225U INFECTIOUS DISEASE (BACTERIAL OR VIRAL RESPIRATORY TRACT INFECT 298.60 298.60 0226U SURROGATE VIRAL NEUTRALIZATION TEST (SVNT), SEVERE ACUTE RESP 42.28 42.28 0240U INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION), PATHOGE 142.63 142.63 0241U INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION), PATHOGE 142.63 142.63 10021 fine needle aspiration; without imaging guidance 56.68 108.77 10040 acne surgery (eg, marsupialization, opening or removal of 68.76 78.15 10060 drainage of abscess 72.94 84.15 10061 drainage of abscess 130.05 144.89 10080 incision and drainage of pilonidal cyst; 74.55 124.22 10081 incision and drainage of pilonidal cyst; 130.66 196.08 10120 incision and removal of foreign body, subcutaneous tissues; 71.53 102.72 10121 incision and removal of foreign body, subcutaneous tissues; 146.44 200.35 10140 drainage of blood effusion 93.45 118.28 10160 puncture aspiration of abscess, hematoma, bulla, or cyst 75.25 96.14 10180 incision and drainage, complex, postoperative wound infection 137.91 177.58 11000 surgical cleansing of skin 26.54 41.69 11001 debridement of extensive eczematous or infected skin; each additional 10% of 13.38 13.38 11004 debridement of skin, subcutaneous tissue, muscle and fascia for necrotizing 475.29 475.29 11005 debridement of skin, subcutaneous tissue, muscle and fascia for necrotizing 620.28 620.28 11006 debridement of skin, subcutaneous tissue, muscle and fascia for necrotizing 586.88 586.88 11008 removal of prosthetic material or mesh, abdominal wall for necrotizing soft 223.60 223.60 11042 debridement; 37.98 57.66 11043 debridement; 184.60 210.35 11044 debridement; 254.01 287.33 11055 paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); single 19.06 37.22 11056 paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); two to 26.88 45.65 11057 paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); more 34.90 54.87 11200 removal of skin tags 53.04 62.43 11201 removal of skin tags, multiple fibrocutaneous tags, any area; each additional 13.53 14.75 11300 shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; 23.98 51.54 11301 shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; 40.77 71.05 11302 shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; 50.56 85.08 11303 shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; 59.30 99.89 11305 shaving of epidermal or dermal lesion, single lesion, scalp, 30.36 53.36 11306 shaving of lesion scalp/neck/hand/etc .6- 1.0 cm 45.98 73.84 11307 shaving of epidermal or dermal lesion, single lesion, scalp, 54.21 87.22 11308 shaving of epidermal or dermal lesion, single lesion, scalp, 65.22 98.23 11310 shaving of epidermal or dermal lesion, single lesion, face, 34.72 64.40 11311 shaving of epidermal or dermal lesion, single lesion, face, 50.86 82.05 11312 shaving of epidermal or dermal lesion, single lesion, face, 58.40 94.74 11313 shaving of epidermal or dermal lesion, single lesion, face, 78.13 118.71 11400 excision, benign lesion including margins, except skin tag (unless listed 57.90 87.57 11401 removal of skin lesion 77.22 108.11 11402 removal of skin lesion 85.52 120.66 11403 removal skin lesion 108.81 139.10 11404 amb surg exc ben lesions trunk arm legs 3.0 to 4.0 121.21 158.46 11406 amb surg exc ben lesion trunk arm leg over 4.0 cm 181.72 224.42 11420 excision, benign lesion including margins, except skin tag (unless listed 62.77 88.81 11421 removal of skin lesion 84.97 115.56 11422 removal of skin lesion 102.46 129.11 11423 amb surg exc ben lesion scalp neck hand 2.0 to 3.0 119.67 150.56 11424 amb surg exc ben lesion scalp neck hand 3.0 to 4.0 138.09 173.83 11426 amb surg exc ben lesion scalp neck hand over 4.0 211.34 250.11 11440 excision, other benign lesion including margins (unless listed elsewhere), 75.02 97.14 11441 removal of skin lesion 98.74 123.57 11442 excision, other benign lesion including margins (unless listed elsewhere), 110.25 139.32 11443 amb surg exc ben lesion face ears nose 2.0 to 3.0 136.52 167.71 11444 amb surg exc ben lesion face ears nose 3.0 to 4.0 175.39 212.04 11446 excision, other benign lesion (unless listed elsewhere), face, 248.62 289.51 11450 exc skin for hidradenitis primary suture/axillary. 180.72 263.99 11451 exc skin for hidradenitis w other closure/axillary 239.12 345.71 11462 exc skin for hidradenitis w prim suture/inguinal 173.71 260.32 11463 exc skin for hidradenitis w oth closure/inguinal 243.86 355.31 11470 exc skin for hidradenitis w primary closure 205.96 290.14 11471 exc skin for hidradenitis with other closure 259.46 365.15 11600 removal of skin lesion 87.42 135.26 11601 removal of skin lesion 113.14 167.35 11602 removal of skin lesion 124.53 183.89 11603 excision malignant lesion truck arms or legs diame 148.22 209.39 11604 amb surg excision malignant lesion 3.0 to 4.0 cm 162.92 231.37 11606 amb surg excision malignant lesion over 4.0 cm 241.95 326.74 11620 removal of skin lesion 88.75 138.11 11621 removal of skin lesion 114.38 168.88 11622 removal of skin lesion 131.95 191.31 11623 excision malignant lesion diameter 2 to 3 cm. 162.78 223.95 11624 amb surg exc malignant lesion 3.0 to 4.0 scalp etc 185.17 252.09 11626 amb surg exc malignant lesion 4.0 scalp neck 231.91 307.31 11640 removal of skin lesion 93.48 144.35 11641 removal of skin lesion 122.08 177.81 11642 removal of skin lesion 144.11 205.28 11643 amb surg exc malignant lesion face ears 2.0 to 3.0 180.22 242.00 11644 amb surg exc malignant lesion face ears 3.0 to 4.0 224.74 298.94 11646 amb surg exc malignant lesion face ears over 4.0 316.51 394.95 11720 debridement of nail(s) by any method(s); one to five 14.03 24.02 11721 debridement of nail(s) by any method(s); six or more 23.97 34.58 11730 removal of nail 48.60 76.17 11732 avulsion of nail plate, partial or complete, simple; each additional nail plate 25.26 35.55 11740 evacuation of subungual hematoma 25.05 34.45 11750 removal of nail bed 138.25 164.90 11755 biopsy of nail unit (eg, plate, bed, matrix, hyponychium, proximal and lateral 68.81 102.42 11760 reconstruction of nail bed 102.77 153.04 11762 reconstruction of nail bed 158.77 206.91 11765 wedge excision of skin of nail fold (eg, for ingrown toenail) 52.76 96.99 11770 amb surg exc pilonidal cyst/sinus simple 139.28 197.42 11771 amb surg exc pilonidal cyst/sinus extensive 322.58 406.16 11772 amb surg exc pilonidal cyst/sinus complicated 420.22 492.89 11900 injection into skin lesions 25.01 43.18 11901 injection, intralesional; 38.92 54.98 11960 insertion of tissue expender. 710.46 710.46 11970 replacement of tissue expander with permanent prosthesis 467.48 467.48 11971 removal of tissue expander(s) without insertion of prosthesis 230.44 344.61 11976 removal, implantable contraceptive capsule 79.29 116.83 11980 subcutaneous hormone pellet (implantation of estradiol and/or testosterone) 66.60 83.25 11981 insert drug implant drevice 67.91 103.75 11982 remove drug implant device 82.86 119.58 11983 remove/insert drug implant 151.73 186.10 12001 repair of recent wound 81.84 113.02 12002 amb surg simple repair superficial wound 2.5-7.5 90.81 120.50 12004 simple rep superf wds sca neck axil ext gen tru/ex 106.82 142.24 12005 amb surg simple repair superficial wound 12.5-20.0 133.20 177.42 12006 amb surg simple repair superficial wound 20.0-30.0 168.33 220.41 12007 amb surg simple repair superficial wound over 30.0 192.40 249.64 12011 amb surg simple repair superficial wound 2.5 cm 84.61 120.04 12013 amb surg simple repair superficial wound 2.5-5.0 96.50 132.53 12014 amb surg simple repair superficial wound 5.0-7.5 116.25 156.53 12015 amb surg simple repair superficial wound 7.5-12.5 145.93 196.81 12016 amb surg simple repair superficial wound 12.5-20.0 178.16 235.40 12017 amb surg simple repair superficial wound 20.0-30.0 212.13 212.13 12018 amb surg simple repair superficial wound over 30.0 262.19 262.19 12020 treatment of superficial wound dehiscence.
Recommended publications
  • Decompressive Craniectomy Following Severe Traumatic Brain Injury with an Initial Glasgow Coma Scale Score of 3 Or 4

    Decompressive Craniectomy Following Severe Traumatic Brain Injury with an Initial Glasgow Coma Scale Score of 3 Or 4

    Case Report Clinics in Surgery Published: 03 Jul, 2019 Decompressive Craniectomy Following Severe Traumatic Brain Injury with an Initial Glasgow Coma Scale Score of 3 or 4 Afif AFIF* Department of Neurosurgery and Anatomy, Pierre Wertheimer Hospital, France Abstract Background: Decompressive craniectomy is a surgical management option for severe Traumatic Brain Injury (TBI). However, few studies have followed patients with TBI who have a Glasgow Coma Scale (GCS) score of 3 or 4 (out of 15). Decompressive craniectomy has been avoided in such patients owing to poor outcomes and poor functional recoveries in previous cases of treatment using this method. Clinical Presentation: Two patients are presented in our case series. The first suffered severe TBI following an aggression, with a GCS score of 3 and bilaterally dilated unreactive pupils. Brains CT scan showed right frontal fracture, bifrontal hematoma contusion, a fronto-temporo-parietal acute Subdural Hematoma (SDH) with a thickness of 14 mm on the right side, traumatic subarachnoid hemorrhage, with 20 mm of midline shift to the left side, and diffuses brain edema. The second presented with severe TBI following an automobile accident, with a GCS score of 4 and iso- reactive pupils. A brain CT scan showed bilateral fronto-temporal fracture, diffuse brain hematoma contusion, traumatic subarachnoid hemorrhage, right Extradural Hematoma (EDH) and bilateral fronto-temporo-parietal acute SDH that was more pronounced on the right side. Conclusion: Follow-up after the operations showed an Extended Glasgow Outcome Scale (EGOS) score of 8 and a very good functional recovery for both patients. Our case series suggests that in patients with severe TBI and a GCS score of 3 or 4; decompressive craniectomy can be performed OPEN ACCESS with good long-term neurological outcomes.
  • Cranioplasty: Indications, Procedures, and Outcome – an Institutional Experience Syed M

    Cranioplasty: Indications, Procedures, and Outcome – an Institutional Experience Syed M

    OPEN ACCESS Editor: James I. Ausman, MD, PhD For entire Editorial Board visit : University of California, Los http://www.surgicalneurologyint.com Angeles, CA, USA SNI: General Neurosurgery Original Article Cranioplasty: Indications, procedures, and outcome – An institutional experience Syed M. Andrabi, Arif H. Sarmast, Altaf R. Kirmani, Abdul R. Bhat Department of Neurosurgery, Sher I Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India E‑mail: Syed M. Andrabi ‑ [email protected]; *Arif H. Sarmast ‑ [email protected]; Altaf R. Kirmani ‑ [email protected]; Abdul R. Bhat ‑ [email protected] *Corresponding author Received: 27 January 17 Accepted: 16 March 17 Published: 26 May 17 Abstract Background: Cranioplasty, the repair of a skull vault defect by insertion of an object (bone or nonbiological materials such as metal or plastic plates), is a well‑known procedure in modern neurosurgery. Brain protection and cosmetic aspects are the major indications of cranioplasty. A retroprospective study was conducted for evaluating the indications, materials used, complications, and outcome of cranioplasty. Methods: This study was prospective from August 2013 to September 2015 and retrospective from August 2010 to July 2013. In the retrospective study, patients files were retrieved from the mentioned date (August 2010 to July 2013) from the medical records and the findings were recorded. Abstracted data included age at the time of cranioplasty (years), sex (male or female), medical comorbidities (hypertension,
  • Case Series Sinking Skin Flap Syndrome Following Posttraumatic Hydrocephalus

    Case Series Sinking Skin Flap Syndrome Following Posttraumatic Hydrocephalus

    Hindawi Case Reports in Neurological Medicine Volume 2021, Article ID 6682310, 8 pages https://doi.org/10.1155/2021/6682310 Case Series Sinking Skin Flap Syndrome following Posttraumatic Hydrocephalus Ashish Chugh, Prashant Punia , and Sarang Gotecha Dr. D. Y. Patil Medical College and Hospital, Pimpri, Pune, Maharashtra, India Correspondence should be addressed to Prashant Punia; [email protected] Received 21 November 2020; Revised 8 January 2021; Accepted 11 January 2021; Published 9 February 2021 Academic Editor: Tapas Kumar Banerjee Copyright © 2021 Ashish Chugh et al. (is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction. Complications following craniotomy are not uncommon and Sinking Skin Flap Syndrome (SSFS) constitutes a rare entity that may present after a large Decompressive Craniectomy. Although the entity is widely reported, the literature mostly consists of case reports. Authors present a case series of three patients with review of literature highlighting the various factors which can prove therapeutic and can help in avoidance of complications. Materials and Methods. (e study was conducted over a period of 3 years, from 2016 to 2019, and included 212 patients who underwent unilateral Decompressive Craniectomy (DC) for trauma in our institute. All 212 patients underwent a similar DC following a strict institutional protocol and the craniectomies were performed by the same surgical team. At total of 160 patients survived and elective cranioplasty was planned at a 3-month interval. Out of a total of 160 patients who survived, 38 developed hydrocephalus, 3 patients presented with hydrocephalus acutely and had to be shunted before cranioplasty and underwent ventriculoperitoneal (VP) shunting on the opposite side of craniectomy.
  • Partial Nephrectomy for Renal Cancer: Part I

    Partial Nephrectomy for Renal Cancer: Part I

    REVIEW ARTICLE Partial nephrectomy for renal cancer: Part I BJUIBJU INTERNATIONAL Paul Russo Department of Surgery, Urology Service, and Weill Medical College, Cornell University, Memorial Sloan Kettering Cancer Center, New York, NY, USA INTRODUCTION The Problem of Kidney Cancer Kidney Cancer Is The Third Most Common Genitourinary Tumour With 57 760 New Cases And 12 980 Deaths Expected In 2009 [1]. There Are Currently Two Distinct Groups Of Patients With Kidney Cancer. The First Consists Of The Symptomatic, Large, Locally Advanced Tumours Often Presenting With Regional Adenopathy, Adrenal Invasion, And Extension Into The Renal Vein Or Inferior Vena Cava. Despite Radical Nephrectomy (Rn) In Conjunction With Regional Lymphadenectomy And Adrenalectomy, Progression To Distant Metastasis And Death From Disease Occurs In ≈30% Of These Patients. For Patients Presenting With Isolated Metastatic Disease, Metastasectomy In Carefully Selected Patients Has Been Associated With Long-term Survival [2]. For Patients With Diffuse Metastatic Disease And An Acceptable Performance Status, Cytoreductive Nephrectomy Might Add Several Additional Months Of Survival, As Opposed To Cytokine Therapy Alone, And Prepare Patients For Integrated Treatment, Now In Neoadjuvant And Adjuvant Clinical Trials, With The New Multitargeted Tyrosine Kinase Inhibitors (Sunitinib, Sorafenib) And Mtor Inhibitors (Temsirolimus, Everolimus) [3,4]. The second groups of patients with kidney overall survival. The explanation for this cancer are those with small renal tumours observation is not clear and could indicate (median tumour size <4 cm, T1a), often that aggressive surgical treatment of small incidentally discovered in asymptomatic renal masses in patients not in imminent patients during danger did not counterbalance a population imaging for of patients with increasingly virulent larger nonspecific abdominal tumours.
  • Core Neurosurgery

    Core Neurosurgery

    BAYLOR SCOTT & WHITE TEXAS SPINE & JOINT HOSPITAL NEUROLOGICAL SURGERY CLINICAL PRIVILEGES NAME: ________________________________ Initial appointment Reappointment All new applicants must meet the following requirements as approved by the governing body. To be eligible to apply for core privileges in neurological surgery, the initial applicant must meet the following criteria: Successful completion of ACGME or American Osteopathic Association accredited residency in neurological surgery. Required previous experience: Applicants for initial appointment must be able to demonstrate the performance of at least 50 neurological surgical procedures, reflective of the scope of privileges requested, during the last 12 months or demonstrate successful completion of residency or fellowship within the past 12 months. Reappointment requirements: To be eligible to renew core privileges in Neurological Surgery, the applicant must meet the following maintenance of privilege criteria: Current demonstrated competence and an adequate volume of neurological surgery procedures with acceptable results, reflective of the scope of privileges requested, for the past 24 months based on results of ongoing professional practice evaluation and outcomes. Evidence of current ability to perform privileges requested is required of all applicants for renewal of privileges NEUROLOGICAL SURGERY CORE PRIVILEGES Requested: Admit, evaluate, diagnose, consult and provide nonoperative and pre-, intran, and postoperative care to patients of all ages presenting with injuries
  • Neurosurgery

    Neurosurgery

    KALEIDA HEALTH Name ____________________________________ Date _____________ DELINEATION OF PRIVILEGES - NEUROSURGERY All members of the Department of Neurosurgery at Kaleida Health must have the following credentials: 1. Successful completion of an ACGME accredited Residency, Royal College of Physicians and Surgeons of Canada, or an ACGME equivalent Neurosurgery Residency Program. 2. Members of the clinical service of Neurosurgery must, within five (5) years of appointment to staff, achieve board certification in Neurosurgery. *Maintenance of board certification is mandatory for all providers who have achieved this status* Level 1 (core) privileges are those able to be performed after successful completion of an accredited Neurosurgery Residency program. The removal or restriction of these privileges would require further investigation as to the individual’s overall ability to practice, but there is no need to delineate these privileges individually. PLEASE NOTE: Please check the box for each privilege requested. Do not use an arrow or line to make selections. We will return applications that ignore this directive. LEVEL I (CORE) PRIVILEGES Basic Procedures including: Admission and Follow-Up Repair cranial or dural defect or lesion History and Physical for diagnosis and treatment plan* Seizure Chest tube placement Sterotactic framed localization of lesion Debride wound Sterotactic frameless localization Endotracheal intubation Transsphenoidal surgery of pituitary lesion Excision of foreign body Trauma Insertion of percutaneous arterial
  • Reversible Signal Abnormalities in the Hippocampus and Neocortex After Prolonged Seizures

    Reversible Signal Abnormalities in the Hippocampus and Neocortex After Prolonged Seizures

    Reversible Signal Abnormalities in the Hippocampus and Neocortex after Prolonged Seizures Stephen Chan, Steven S. M. Chin, Krishnan Kartha, Douglas R. Nordli, Robert R. Goodman, Timothy A. Pedley, and Sadek K. Hilal PURPOSE: To investigate the phenomenon of reversible increased signal intensity of medial temporal lobe structures and cerebral neocortex seen on MR images of six patients with recent prolonged seizure activity. METHODS: After excluding patients with known causes of reversible signal abnormalities (such as hypertensive encephalopathy), we retrospectively reviewed the clinical findings and MR studies of six patients whose MR studies showed reversible signal abnor- malities. MR pulse sequences included T2-weighted spin-echo coronal views or conventional short-tau inversion-recovery coronal images of the temporal lobes. RESULTS: All six MR studies showed increased signal intensity within the medial temporal lobe, including the hippocampus in five studies. All follow-up MR examinations showed partial or complete resolution of the hyperin- tensity within the medial temporal lobe and the neocortex. In one patient, results of a brain biopsy revealed severe cerebral cortical gliosis. Temporal lobectomy performed 4 years later showed moderate cortical gliosis and nonspecific hippocampal cell loss and gliosis. CONCLUSION: Sig- nificant hyperintensity within the temporal lobe is demonstrable on MR images after prolonged seizure activity, suggestive of seizure-induced edema or gliosis. Damage to medial temporal lobe structures by prolonged seizure activity indicates a possible mechanism of epileptogenic disorders. Index terms: Brain, magnetic resonance; Brain, temporal lobe; Hippocampus; Seizures AJNR Am J Neuroradiol 17:1725–1731, October 1996 Prolonged seizure activity is associated with character of the acute neuronal loss in the hip- long-lasting neurologic damage and even death pocampus seen after an episode of status epi- in humans (1–3); prompt treatment is required lepticus is different from the neuronal loss and to forestall irreversible changes (4).
  • Wrvus: Do They Really Measure the Workload and Complexity of What We Do?

    Wrvus: Do They Really Measure the Workload and Complexity of What We Do?

    wRVUs: Do They Really Measure the Workload and Complexity Of What We Do? Raj S. Pruthi MD MHA FACS Rhodes Distinguished Professor and Chair Department of Urology The University of North Carolina at Chapel Hill INTRODUCTION Productivity-based Compensation • InCreasing use of wRVU in employed Compensation models • 2007 (16%) à 2016 (> 60%) • Use of benChmarked data (MGMA, AMGA, SC) to determine compensation/produCtivity ($/wRVU) • e.g. AMGA $441,836 / 7649 = $57.76/wRVU 2 INTRODUCTION wRVU • RBRVS - Developed for HCFA by Hsaio et al (1986-92) • Passed in 1989 -- implemented in 1992 INTRODUCTION Work RVU x Work GPCI + Practice Expense RVU x PE GPCI Conversion Payment = x FaCtor Rate + Malpractice RVU x MP GPCI GPCI = geographiC praCtiCe Cost index INTRODUCTION • RVUs à metric of physician productivity • RVUs : CPT code 405 urologiCal serviCes 22 383 Work = Time x Intensity INTRODUCTION Work 100 units INTRODUCTION • RVU assignments initially made in consultation with nominees from various medical specialties • Quarterly adjustments based on survey data • Zero sum game INTRODUCTION Changes to Work RVUs RUC Summary of Recommendation INTRODUCTION Who Gets Surveys? • Respondents seleCted by AUA by random sampling • May be sub-speCialty, e.g. prosthetiCs • May be general, e.g. cysto with dilation • Private praCtiCe (small & large), hospital-based, and aCademiC • Need at least 30-50 responses -- ideally >100 responses INTRODUCTION • Subjective methodology linked with compensation • Accurate measure of surgical complexity? workload? effort? time?
  • ICD~10~PCS Complete Code Set Procedural Coding System Sample

    ICD~10~PCS Complete Code Set Procedural Coding System Sample

    ICD~10~PCS Complete Code Set Procedural Coding System Sample Table.of.Contents Preface....................................................................................00 Mouth and Throat ............................................................................. 00 Introducton...........................................................................00 Gastrointestinal System .................................................................. 00 Hepatobiliary System and Pancreas ........................................... 00 What is ICD-10-PCS? ........................................................................ 00 Endocrine System ............................................................................. 00 ICD-10-PCS Code Structure ........................................................... 00 Skin and Breast .................................................................................. 00 ICD-10-PCS Design ........................................................................... 00 Subcutaneous Tissue and Fascia ................................................. 00 ICD-10-PCS Additional Characteristics ...................................... 00 Muscles ................................................................................................. 00 ICD-10-PCS Applications ................................................................ 00 Tendons ................................................................................................ 00 Understandng.Root.Operatons..........................................00
  • Infection on Neurological Implanted Devices

    Infection on Neurological Implanted Devices

    ECCMID Amsterdam 09.04.2016 Challenging complex infections for ID physicians Infection on neurological implanted devices Anna Conen, MD MSc Deputy Head Physician Division of Infectious Diseases and Hospital Hygiene ESCMIDKantonsspital Aarau, eLibrary Switzerland by author Disclosures Received travel grants from Gilead, Merck Sharp Dohme, ViiV Healthcare, Bristol- Myers Squibb and Janssen. ESCMID eLibrary by author Outline • Diagnosis of implant-associated infections • Treatment concepts of implant-associated infections • Specific infections associated with the following implants: Craniotomy/bone flap Cranioplasty Deep brain stimulator Ventriculo-peritoneal shunt Neurological implants ESCMIDSpinal cord stimulator External ventricular eLibrary drainage Ventriculo-atrial shunt by author Risk of implant-associated infections Device No. inserted in the US, Infection rate, % per year Fracture fixation devices 2,000,000 5–10 Dental implants 1,000,000 5–10 Joint prostheses 600,000 1–3 Neurosurgical implants 450,000 3–15 Cardiac pacemakers 300,000 1–7 Mammary implants 130,000 1–2 Mechanical heart valves 85,000 1–3 Penile implants 15,000 1–3 Heart assist devices 700 25–50 ESCMID eLibraryDarouiche RO. Clin Infect Dis 2011; 33:1567-1572 by author Concept and diagnosis of biofilm Biofilm Sonication - Bacteria adhere to implant - Sonication of implants*: surface detachment of biofilm - Embed in a matrix - Sonication fluid plated on - In stationary growth phase culture media - Slowly replicate Standard method: 3 Sonication of tissue biopsies implant: Sensitivity ~60% Sensitivity 80-90% *Cranioplasty, shunts, screws, plates, stimulators, etc. Zimmerli W. J Infect Dis. 1982;146(4):487-97. Trampuz A. NEJM 2007;357:654–663. Portillo M. J Clin Microbiol 2015;53(5):1622-7.
  • Urology Scientific Session Monday, September 28, 2020

    Urology Scientific Session Monday, September 28, 2020

    Urology Scientific Session Monday, September 28, 2020 Moderators/Panelists: Drs. Sabine Zundel, Sameh Shehata, Holger Till, Yuri Kozlov, Philipp Szavay, Eduardo Perez (S26) PNEUMOVESICOSCOPIC CORRECTION OF PRIMARY VESICOURETERAL REFLUX (VUR) IN CHILDREN. - OUR INITIAL EXPERIENCE- A. M. Benaired, Pediatric, Surgeon; H Zahaf, Pediatric, Surgeon; Military Central Hospital Purpose: Vesicoureteral reflux is a common urological abnormality predisposing risk of childhood hypertension and chronic renal failure. It is called primitive when it is due to an abnormality of the vesicoureteral junction. Different treatment approaches have been proposed a long time. Two main trends can be identified, conservative and operative approach. The main objective of our prospective study is to demonstrate the feasibility of vesicoscopic crosstrigonal ureteral reimplantation under CO2 pneumovesicum in treatment on primary vesicoureteral reflux and analyze results of this approach. Methods: A total of 60 patients underwent transvesicoscopic ureteral reimplantation (33 boys, 27 girls) by the same surgeon from Mai 2011 to Mai 2015. All patients had primary vesicoureteral reflux, and surgery was performed because of breakthrough urinary tract infection despite antibiotic prophylaxis, persistent high grade of vesicoureteral reflux especially in association with significant renal scarring, mean age at operation was 47.47 month (5 month - 12 years). Of the 60 patients, 34 had bilateral reflux and 26 had unilateral reflux. The reflux grade in the total of 94 ureters was grade IV, V in 59.57%, grade III in 35.11% and grade II in 5.32% in association with contralateral high grade vesicoureteral reflux. Our surgical methods followed those reported by Valla et al. Results: The transvesicoscopic procedure was successfully completed in all patients without perioperative complication except one case of pneumoperitoneum that required exsufflation by open laparoscopy.
  • Laparoscopic Ureteral Repair in Gynaecological Surgery Carlo De Ciccoa, Anastasia Ussiab and Philippe Robert Koninckxb,C

    Laparoscopic Ureteral Repair in Gynaecological Surgery Carlo De Ciccoa, Anastasia Ussiab and Philippe Robert Koninckxb,C

    Laparoscopic ureteral repair in gynaecological surgery Carlo De Ciccoa, Anastasia Ussiab and Philippe Robert Koninckxb,c aDepartment of Obstetrics and Gynaecology, Purpose of review University Hospital A. Gemelli, Universita` Cattolica del Sacro Cuore, bGruppo Italo-Belga, Rome, Italy and To review laparoscopic surgery in the treatment options for ureteral lesions in cDepartment of Obstetrics and Gynaecology, gynaecological surgery. University Hospital Gasthuisberg, Katholieke Recent findings Universiteit Leuven, Leuven, Belgium Laparoscopic treatment of ureteral injuries has been increasingly reported over the past Correspondence to Dr Carlo De Cicco, Department of Obstetrics and Gynaecology, University Hospital A. years. Treatment has progressively shifted from ureteroneocystostomy performed by Gemelli, Universita` Cattolica del Sacro Cuore, Largo F. laparotomy to less invasive treatment options such as ureteral stenting or dilatation in Vito 1, 00168 Rome, Italy Tel: +39 06 30155131; case of stricture, stenting under laparoscopic guidance and laparoscopic stitching of e-mail: [email protected] lacerations, laparoscopic ureteral reanastomosis or laparoscopic Current Opinion in Obstetrics and Gynecology ureteroneocystostomy for transections. Deep endometriosis surgery of an associated 2011, 23:296–300 hydronephrosis is associated with a high incidence of ureteral lesions making preoperative stenting desirable in order to facilitate the eventual repair, while avoiding the more problematic insertion of a stent after a lesion is made. The available data confirm the excellent outcome of stenting obstructive lesions. When stenting proves difficult or in case of a ureteral leakage, laparoscopic aided stenting is strongly suggested, in order to avoid further damage while permitting simultaneous repair if necessary. Laparoscopic suturing of a laceration over a stent is clearly superior to stenting only.